A Randomized, Open-label, Parallel Group Study to Compare the Pharmacokinetics, Pharmacodynamics and Safety and Tolerability of a Subcutaneous Formulation With an Intravenous Formulation of ARGX-113 in Healthy Male Subjects

Trial Profile

A Randomized, Open-label, Parallel Group Study to Compare the Pharmacokinetics, Pharmacodynamics and Safety and Tolerability of a Subcutaneous Formulation With an Intravenous Formulation of ARGX-113 in Healthy Male Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs ARGX 113 (Primary) ; ARGX 113 (Primary)
  • Indications Immune thrombocytopenic purpura; Myasthenia gravis; Pemphigus vulgaris
  • Focus Adverse reactions
  • Sponsors argenx
  • Most Recent Events

    • 31 Oct 2017 New trial record
    • 30 Oct 2017 According to an argenx media release, the first subject has been dosed in this trial.
    • 26 Oct 2017 According to an argenx media release, subcutaneous dosing in this trial expected in Q4 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top